Lancet [2013] Oct 31 [Epub ahead of print] (J.Cummings, S.Isaacson, R.Mills, H.Williams, K.Chi-Burris, A.Corbett, R.Dhall, C.Ballard)
Parkinson's Disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in some people with Parkinson's Disease. Pimavanserin, which is a serotonin 5-HT2A inverse agonist that is presently being assessed, aims to treat Parkinson's Disease psychosis. A clinical trial assessed the effect of Pimavanserin.
They took 40mg pimavanserin per day. The primary measure was the antipsychotic benefit using the Parkinson's disease-adapted scale for assessment of positive symptoms (SAPS-PD). According to the Parkinson's disease-adapted scale for assessment of positive symptoms (SAPS-PD) those people taking pimavanserin reduced their score by 5.79 compared with a reduction of 2.73 by those taking a placebo. Over 10% of the patients discontinued because of an adverse event. However, in previous clinical trials there was either no effect or it was beneficial for some but not all measures of psychosis
No comments:
Post a Comment